Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 9/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.75 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.75 |
| ▸ | POLL | Q9UGP5 | 7/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Garcinol SCHEMBL29395703 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL19565392 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL31345886 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815758 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815733 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23607580 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL25049796 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL23815760 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Guttiferone F SCHEMBL4607088 | 1.00 | EP300 (0.75) | EP300HDAC11KAT2BPTGESHDAC8 | |
| Xanthochymol SCHEMBL14867275 | 0.92 | EP300 (0.63) | EP300HDAC11KAT2BPTGESHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1026 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605407-B2 | Methods to induce terminal differentiation in stem cells by interfering with DNA replication, methods of inducing pancreatic differentiation, and differentiated cells obtained thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-04-21 | — | — | US | claimed |
| EP-4725505-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR SKIN DISORDER ASSOCIATED WITH HISTONE DEACETYLASE 4 ABNORMALITY | National University Corporation Kobe University (JP) | 2026-04-15 | — | — | EP | claimed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| US-20250075176-A1 | COMPOSITIONS COMPRISING HISTONE ACETYLTRANSFERASE INHIBITORS OR REVERSE TRANSCRIPTASE INHIBITORS AND USE THEREOF | FOREVE LABS LTD. (IL) | 2025-03-06 | — | — | US | claimed |
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | claimed |
| EP-4490269-A1 | COMPOSITIONS COMPRISING HISTONE ACETYLTRANSFERASE INHIBITORS OR REVERSE TRANSCRIPTASE INHIBITORS AND USE THEREOF | Foreve Labs Ltd. (IL) | 2025-01-15 | — | — | EP | claimed |
| WO-2025009296-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR SKIN DISORDER ASSOCIATED WITH HISTONE DEACETYLASE 4 ABNORMALITY | 国立大学法人神戸大学 | 2025-01-09 | — | — | WO | claimed |
| WO-2024233640-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240366661-A1 | COMPOSITIONS FOR AND METHODS OF TREATING A SUBJECT HAVING INFLAMMATION | THE GEORGE WASHINGTON UNIVERSITY | 2024-11-07 | — | — | US | claimed |
| US-20240269106-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN (IN) | 2024-08-15 | — | — | US | claimed |
| EP-1254209-B1 | COMPOSITION COMPRISING HYDROXYCITRIC ACID AND GARCINOL FOR WEIGHT-LOSS | SABINSA CORP (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2005025500-A2 | PROCESS FOR PREPARING WATER SOLUBLE DITERPENES AND THEIR APPLICATIONS | MAJEED MUHAMMED (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050051483-A1 | Process for preparing water soluble diterpenes and their applications | SAMI LABS LTD. (IN) | 2005-03-10 | — | — | US | claimed |
| EP-1254209-A4 | BIOAVAILABLE COMPOSITION OF NATURAL AND SYNTHETIC HCA | SABINSA CORP (US) | 2004-09-08 | — | — | EP | claimed |
| CN-1521164-A | Pyran isoflavone molluscacide synthesizing method and formulation | 中国人民解放军南京军区联勤部军事医 | 2004-08-18 | — | — | CN | claimed |
| US-20020187943-A1 | Bioavailable composition of natural and synthetic hca | SAMI LABS LTD. (IN) | 2002-12-12 | — | — | US | claimed |
| EP-1254209-A2 | BIOAVAILABLE COMPOSITION OF NATURAL AND SYNTHETIC HCA | Sabinsa Corporation (US) | 2002-11-06 | — | — | EP | claimed |
| WO-2002060865-A1 | PROCESS OF OBTAINING HIGH PURITY OF ZEAXANTHIN, CRYPTOXANTHIN & OTHER CAROTENOIDS FROM BYADAGI CHILI/CHAPPATTA CHILI & CAROTENOID COMPOSITION | SABINSA CORPORATION (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002014477-A2 | BIOAVAILABLE COMPOSITION OF NATURAL AND SYNTHETIC HCA | SABINSA CORPORATION (US) | 2002-02-21 | — | — | WO | claimed |
| US-5972357-A | CONTAINING POLYISOPRENYLATED BENZOPHENONE DERIVATIVES AS EFFECTIVE INGREDIENTS AND HAVING A VARIETY OF FUNCTIONS FOR MAINTAINING HEALTH SUCH AS ANTI-ULCER ACTIVITY, THE MAILLARD REACTION INHIBITING ACTIVITY, ANTI-OXIDATION ACTIVITY, OXYGEN | KIKKOMAN CORPORATION (JP) | 1999-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | HBB, HBG1, HBZ | EP300 4879/4885HDAC11 4747/4885KAT2B 4349/4885 |
| US-12605407-B2 | Methods to induce terminal differentiation in stem cells by interfering with DNA replication, methods of inducing pancreatic differentiation, and differentiated cells obtained thereof | CCND1, CCNB3, MKI67 | EP300 2856/4885HDAC11 3213/4885KAT2B 2199/4885 |
| US-20240269106-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | EP300, HDAC1, HDAC3 | EP300 1/4885HDAC11 5/4885KAT2B 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.